Clinical Trial Update: PRIME: Pilot Study Evaluating Percutaneous Vaccination of BCG for Bladder Cancer [EARLY_Phase 1]

View source ↗

Summary

The PRIME pilot study evaluating percutaneous BCG vaccination for bladder cancer has completed its EARLY Phase 1 trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• BCG (Bacillus Calmette-Guérin)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Bladder Cancer | EARLY_Phase 1 | Status: COMPLETED